Ramandeep Rattan

Longitudinal and stability-aware analysis reveals treatment-specific microRNA response signatures following immune-reconstitution and B-cell-targeted therapies in multiple sclerosis

This study identifies treatment-specific miRNA response signatures in RRMS patients following cladribine or ocrelizumab, revealing distinct molecular programs associated with each therapy.

Aging-Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment

This study identifies succinate accumulation in aged ovarian tumor microenvironments as a driver of Treg dysfunction, suggesting metabolic targeting as a strategy to restore antitumor immunity.

Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors

This study shows CPI-613 reduces tumor growth in chemoresistant ovarian tumors by inhibiting mitochondrial function and enhancing chemotherapy response.

Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

Maresin-1 promotes neuroprotection and prevents disease progression in experimental models of multiple sclerosis through metabolic reprogramming and shaping innate and adaptive disease-associated cell types

This study shows that MaR1 treatment reduces inflammation, protects neurons, and improves metabolism in a mouse model of multiple sclerosis.

Pyruvate dehydrogenase dependent metabolic program affects oligodendrocyte maturation and remyelination

This study shows that pyruvate dehydrogenase (Pdh) activity is critical for oligodendrocyte maturation and remyelination by regulating mitochondrial respiration and Olig1 acetylation.

Blood-based untargeted metabolomics in Relapsing-Remitting Multiple Sclerosis revealed the testable therapeutic target

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.